Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Free Cash Flow (2016 - 2025)

Celldex Therapeutics has reported Free Cash Flow over the past 16 years, most recently at -$65.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$65.2 million for Q4 2025, down 96.26% from a year ago — trailing twelve months through Dec 2025 was -$213.7 million (down 33.79% YoY), and the annual figure for FY2025 was -$213.7 million, down 33.79%.
  • Free Cash Flow for Q4 2025 was -$65.2 million at Celldex Therapeutics, down from -$49.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for CLDX hit a ceiling of -$12.1 million in Q2 2021 and a floor of -$65.2 million in Q4 2025.
  • Median Free Cash Flow over the past 5 years was -$29.4 million (2023), compared with a mean of -$32.5 million.
  • Biggest five-year swings in Free Cash Flow: soared 46.11% in 2023 and later crashed 191.81% in 2024.
  • Celldex Therapeutics' Free Cash Flow stood at -$14.9 million in 2021, then plummeted by 47.86% to -$22.0 million in 2022, then crashed by 50.93% to -$33.2 million in 2023, then dropped by 0.1% to -$33.2 million in 2024, then plummeted by 96.26% to -$65.2 million in 2025.
  • The last three reported values for Free Cash Flow were -$65.2 million (Q4 2025), -$49.1 million (Q3 2025), and -$44.7 million (Q2 2025) per Business Quant data.